This trial is testing a new cancer treatment involving TCR-T cells. Participants will receive infusions of the cells, as well as aldesleukin, and doctors will monitor for safety and effectiveness.
- Stomach Cancer
- Cervical Cancer
- Breast Cancer
- Lung Cancer
1 Primary · 3 Secondary · Reporting Duration: Through study completion, up to 5 years
Awards & Highlights
1 Treatment Group
KK-LC-1 TCR-T cells
1 of 1
42 Total Participants · 1 Treatment Group
Primary Treatment: KK-LC-1 TCR-T cells · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Has the FDA sanctioned KK-LC-1 TCR-T cells for clinical usage?
"As this is an initial phase 1 trial, the KK-LC-1 TCR-T cells are deemed to have a safety score of 1 due to the limited amount of clinical data supporting its efficacy and security." - Anonymous Online Contributor
Is there still capacity available for participants in this medical trial?
"Evidenced by the most recent update (dated September 26th 2022) on clinicaltrials.gov, this medical trial is seeking participants who meet its criteria. It was first posted to the site on that same date." - Anonymous Online Contributor
What is the enrollment maximum for this experiment?
"Yes, the evidence on clinicaltrials.gov affirms that this medical study is actively searching for participants. It was first uploaded on September 26th 2022 and updated recently with a goal of recruiting 42 patients from one site." - Anonymous Online Contributor